{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:13:51Z","timestamp":1789902831277,"version":"4.0.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"DOI":"10.7759\/cureus.49782","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T12:13:53Z","timestamp":1701432833000},"source":"Crossref","is-referenced-by-count":2,"title":["The Evolving Role of Vericiguat in Patients With Chronic Heart Failure"],"prefix":"10.7759","author":[{"given":"Ross M","family":"Dies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrie N","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsi J","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan  S","family":"Sinnathamby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah J","family":"Spillers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Potharaju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naina","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2016.25","article-title":"Epidemiology and aetiology of heart failure","volume":"13","author":"Ziaeian B","year":"2016","unstructured":"Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016, 13:368-78. 10.1038\/nrcardio.2016.25","journal-title":"Nat Rev Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12555","article-title":"Highlights in heart failure","volume":"6","author":"Tomasoni D","year":"2019","unstructured":"Tomasoni D, Adamo M, Lombardi CM, Metra M. Highlights in heart failure. ESC Heart Fail. 2019, 6:1105-27. 10.1002\/ehf2.12555","journal-title":"ESC Heart Fail"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5070062","article-title":"Heart failure: diagnosis, management and utilization","volume":"5","author":"Inamdar AA","year":"2016","unstructured":"Inamdar AA, Inamdar AC. Heart failure: diagnosis, management and utilization. J Clin Med. 2016, 5:62. 10.3390\/jcm5070062","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese G","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023, 118:3272-87. 10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2010.165","article-title":"Epidemiology and risk profile of heart failure","volume":"8","author":"Bui AL","year":"2011","unstructured":"Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011, 8:30-41. 10.1038\/nrcardio.2010.165","journal-title":"Nat Rev Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm.2020.04.154","article-title":"Epidemiology and pathogenesis of heart failure with preserved ejection fraction","volume":"21","author":"Nair N","year":"2020","unstructured":"Nair N. Epidemiology and pathogenesis of heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2020, 21:531-40. 10.31083\/j.rcm.2020.04.154","journal-title":"Rev Cardiovasc Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2003.025270","article-title":"Clinical epidemiology of heart failure","volume":"93","author":"Mosterd A","year":"2007","unstructured":"Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007, 93:1137-46. 10.1136\/hrt.2003.025270","journal-title":"Heart"},{"key":"ref8","article-title":"Diagnosis and evaluation of heart failure","volume":"85","author":"King M","year":"2012","unstructured":"King M, Kingery J, Casey B. Diagnosis and evaluation of heart failure. Am Fam Physician. 2012, 85:1161-8.","journal-title":"Am Fam Physician"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2019.03.007","article-title":"Acute heart failure","volume":"30","author":"Sinnenberg L","year":"2020","unstructured":"Sinnenberg L, Givertz MM. Acute heart failure. Trends Cardiovasc Med. 2020, 30:104-12. 10.1016\/j.tcm.2019.03.007","journal-title":"Trends Cardiovasc Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022, 145:e895-e1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.678614","article-title":"Similarities and differences between HFmrEF and HFpEF","volume":"8","author":"Li P","year":"2021","unstructured":"Li P, Zhao H, Zhang J, Ning Y, Tu Y, Xu D, Zeng Q. Similarities and differences between HFmrEF and HFpEF. Front Cardiovasc Med. 2021, 8:678614. 10.3389\/fcvm.2021.678614","journal-title":"Front Cardiovasc Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction","volume":"17","author":"Borlaug BA","year":"2020","unstructured":"Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020, 17:559-73. 10.1038\/s41569-020-0363-2","journal-title":"Nat Rev Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy SP","year":"2020","unstructured":"Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: a review. JAMA. 2020, 324:488-504. 10.1001\/jama.2020.10262","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy005","article-title":"Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study","volume":"39","author":"Lam CS","year":"2018","unstructured":"Lam CS, Gamble GD, Ling LH, et al.. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018, 39:1770-80. 10.1093\/eurheartj\/ehy005","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx515","article-title":"Improved outcomes in patients with ST-elevation myocardial infarction during the last 20\u2009years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014","volume":"38","author":"Szummer K","year":"2017","unstructured":"Szummer K, Wallentin L, Lindhagen L, et al.. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20\u2009years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. Eur Heart J. 2017, 38:3056-65. 10.1093\/eurheartj\/ehx515","journal-title":"Eur Heart J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.08.067","article-title":"Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction","volume":"53","author":"Ezekowitz JA","year":"2009","unstructured":"Ezekowitz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC, McAlister FA. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol. 2009, 53:13-20. 10.1016\/j.jacc.2008.08.067","journal-title":"J Am Coll Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The transition from hypertension to heart failure: contemporary update","volume":"5","author":"Messerli FH","year":"2017","unstructured":"Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: contemporary update. JACC Heart Fail. 2017, 5:543-51. 10.1016\/j.jchf.2017.04.012","journal-title":"JACC Heart Fail"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000039105.49749.6f","article-title":"Lifetime risk for developing congestive heart failure: the Framingham Heart Study","volume":"106","author":"Lloyd-Jones DM","year":"2002","unstructured":"Lloyd-Jones DM, Larson MG, Leip EP, et al.. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002, 106:3068-72. 10.1161\/01.cir.0000039105.49749.6f","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.07.008","article-title":"Diabetes mellitus is an independent predictor for the development of heart failure: A population study","volume":"95","author":"Klajda MD","year":"2020","unstructured":"Klajda MD, Scott CG, Rodeheffer RJ, Chen HH. Diabetes mellitus is an independent predictor for the development of heart failure: A population study. Mayo Clin Proc. 2020, 95:124-33. 10.1016\/j.mayocp.2019.07.008","journal-title":"Mayo Clin Proc"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.8.1879","article-title":"The incidence of congestive heart failure in type 2 diabetes: an update","volume":"27","author":"Nichols GA","year":"2004","unstructured":"Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004, 27:1879-84. 10.2337\/diacare.27.8.1879","journal-title":"Diabetes Care"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000141726.01302.83","article-title":"Predictors of heart failure among women with coronary disease","volume":"110","author":"Bibbins-Domingo K","year":"2004","unstructured":"Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Hulley SB, Grady D, Shlipak MG. Predictors of heart failure among women with coronary disease. Circulation. 2004, 110:1424-30. 10.1161\/01.CIR.0000141726.01302.83","journal-title":"Circulation"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and the risk of heart failure","volume":"347","author":"Kenchaiah S","year":"2002","unstructured":"Kenchaiah S, Evans JC, Levy D, et al.. Obesity and the risk of heart failure. N Engl J Med. 2002, 347:305-13. 10.1056\/NEJMoa020245","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9040248","article-title":"The obesity paradox and heart failure: a systematic review of a decade of evidence","volume":"2016","author":"Oga EA","year":"2016","unstructured":"Oga EA, Eseyin OR. The obesity paradox and heart failure: a systematic review of a decade of evidence. J Obes. 2016, 2016:9040248. 10.1155\/2016\/9040248","journal-title":"J Obes"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1042\/CS20210384","article-title":"Obesity-associated cardiovascular risk in women: hypertension and heart failure","volume":"135","author":"Faulkner JL","year":"2021","unstructured":"Faulkner JL. Obesity-associated cardiovascular risk in women: hypertension and heart failure. Clin Sci (Lond). 2021, 135:1523-44. 10.1042\/CS20210384","journal-title":"Clin Sci (Lond)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.1.55","article-title":"The obesity paradox: body mass index and outcomes in patients with heart failure","volume":"165","author":"Curtis JP","year":"2005","unstructured":"Curtis JP, Selter JG, Wang Y, et al.. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med. 2005, 165:55-61. 10.1001\/archinte.165.1.55","journal-title":"Arch Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.188965","article-title":"Prevention of heart failure: a scientific statement from the American Heart Association councils on epidemiology and prevention, clinical cardiology, cardiovascular nursing, and high blood pressure research; quality of care and outcomes research interdisciplinary working group; and functional genomics and translational biology interdisciplinary working group","volume":"117","author":"Schocken DD","year":"2008","unstructured":"Schocken DD, Benjamin EJ, Fonarow GC, et al.. Prevention of heart failure: a scientific statement from the American Heart Association councils on epidemiology and prevention, clinical cardiology, cardiovascular nursing, and high blood pressure research; quality of care and outcomes research interdisciplinary working group; and functional genomics and translational biology interdisciplinary working group. Circulation. 2008, 117:2544-65. 10.1161\/CIRCULATIONAHA.107.188965","journal-title":"Circulation"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.3490","article-title":"Heart failure in elderly patients: differences in clinical characteristics and predictors of 1-year outcome in the Polish ESC-HF Long-Term Registry","volume":"126","author":"Oziera\u0144ski K","year":"2016","unstructured":"Oziera\u0144ski K, Balsam P, Tymi\u0144ska A, et al.. Heart failure in elderly patients: differences in clinical characteristics and predictors of 1-year outcome in the Polish ESC-HF Long-Term Registry. Pol Arch Med Wewn. 2016, 126:502-13. 10.20452\/pamw.3490","journal-title":"Pol Arch Med Wewn"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpopen17X101013","article-title":"Prognosis following a diagnosis of heart failure and the role of primary care: a review of the literature","volume":"1","author":"Jones NR","year":"2017","unstructured":"Jones NR, Hobbs FR, Taylor CJ. Prognosis following a diagnosis of heart failure and the role of primary care: a review of the literature. BJGP Open. 2017, 1:bjgpopen17X101013. 10.3399\/bjgpopen17X101013","journal-title":"BJGP Open"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1080\/00015385.2021.1890925","article-title":"Heart failure as a complication of COVID-19 infection: systematic review and meta-analysis","volume":"77","author":"Zuin M","year":"2022","unstructured":"Zuin M, Rigatelli G, Bilato C, Zuliani G, Roncon L. Heart failure as a complication of COVID-19 infection: systematic review and meta-analysis. Acta Cardiol. 2022, 77:107-13. 10.1080\/00015385.2021.1890925","journal-title":"Acta Cardiol"},{"key":"ref30","article-title":"Chronic heart failure in the elderly: still a current medical problem","volume":"58","author":"Skrzypek A","year":"2018","unstructured":"Skrzypek A, Mostowik M, Szeliga M, Wilczy\u0144ska-Golonka M, D\u0119bicka-D\u0105browska D, Nessler J. Chronic heart failure in the elderly: still a current medical problem. Folia Med Cracov. 2018, 58:47-56.","journal-title":"Folia Med Cracov"},{"key":"ref31","doi-asserted-by":"crossref","DOI":"10.1053\/euhj.1998.1239","article-title":"Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study","volume":"20","author":"Mosterd A","year":"1999","unstructured":"Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, Grobbee DE. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J. 1999, 20:447-55.","journal-title":"Eur Heart J"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz835","article-title":"Sex differences in heart failure","volume":"40","author":"Lam CS","year":"2019","unstructured":"Lam CS, Arnott C, Beale AL, et al.. Sex differences in heart failure. Eur Heart J. 2019, 40:3859-3868c. 10.1093\/eurheartj\/ehz835","journal-title":"Eur Heart J"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.003116","article-title":"Predicting heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes","volume":"9","author":"Ho JE","year":"2016","unstructured":"Ho JE, Enserro D, Brouwers FP, et al.. Predicting heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes. Circ Heart Fail. 2016, 9:e003116. 10.1161\/CIRCHEARTFAILURE.115.003116","journal-title":"Circ Heart Fail"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7229.236","article-title":"ABC of heart failure. Clinical features and complications","volume":"320","author":"Watson RD","year":"2000","unstructured":"Watson RD, Gibbs CR, Lip GY. ABC of heart failure. Clinical features and complications. BMJ. 2000, 320:236-9. 10.1136\/bmj.320.7229.236","journal-title":"BMJ"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2016-134045","article-title":"The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future","volume":"93","author":"Orsborne C","year":"2017","unstructured":"Orsborne C, Chaggar PS, Shaw SM, Williams SG. The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future. Postgrad Med J. 2017, 93:29-37. 10.1136\/postgradmedj-2016-134045","journal-title":"Postgrad Med J"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3724\/SP.J.1263.2011.00131","article-title":"Cardiac arrhythmia and heart failure: from bench to bedside","volume":"8","author":"Xiao YF","year":"2011","unstructured":"Xiao YF. Cardiac arrhythmia and heart failure: from bench to bedside. J Geriatr Cardiol. 2011, 8:131-2. 10.3724\/SP.J.1263.2011.00131","journal-title":"J Geriatr Cardiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.03.005","article-title":"Heart failure and atrial fibrillation, like fire and fury","volume":"7","author":"Carlisle MA","year":"2019","unstructured":"Carlisle MA, Fudim M, DeVore AD, Piccini JP.  Heart failure and atrial fibrillation, like fire and fury. JACC Heart Fail. 2019, 7:447-56. 10.1016\/j.jchf.2019.03.005","journal-title":"JACC Heart Fail"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2021.33","article-title":"Management of heart failure in patients with chronic kidney disease","volume":"17","author":"Ryan DK","year":"2022","unstructured":"Ryan DK, Banerjee D, Jouhra F. Management of heart failure in patients with chronic kidney disease. Eur Cardiol. 2022, 17:e17. 10.15420\/ecr.2021.33","journal-title":"Eur Cardiol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich PA","year":"2013","unstructured":"Heidenreich PA, Albert NM, Allen LA, et al.. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013, 6:606-19. 10.1161\/HHF.0b013e318291329a","journal-title":"Circ Heart Fail"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020265","article-title":"Long-term trends in the incidence of and survival with heart failure","volume":"347","author":"Levy D","year":"2002","unstructured":"Levy D, Kenchaiah S, Larson MG, et al.. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002, 347:1397-402. 10.1056\/NEJMoa020265","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13646","article-title":"'Time is prognosis' in heart failure: time-to-treatment initiation as a modifiable risk factor","volume":"8","author":"Abdin A","year":"2021","unstructured":"Abdin A, Anker SD, Butler J, et al.. 'Time is prognosis' in heart failure: time-to-treatment initiation as a modifiable risk factor. ESC Heart Fail. 2021, 8:4444-53. 10.1002\/ehf2.13646","journal-title":"ESC Heart Fail"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1590\/s1679-45082013000300022","article-title":"Decompensated heart failure","volume":"11","author":"Mangini S","year":"2013","unstructured":"Mangini S, Pires PV, Braga FG, Bacal F. Decompensated heart failure. Einstein (Sao Paulo). 2013, 11:383-91. 10.1590\/s1679-45082013000300022","journal-title":"Einstein (Sao Paulo)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"62","author":"Yancy CW","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al.. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2013, 62:e147-239. 10.1016\/j.jacc.2013.05.019","journal-title":"J Am Coll Cardiol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2020.0376","article-title":"The treatment of heart failure with reduced ejection fraction","volume":"117","author":"Berliner D","year":"2020","unstructured":"Berliner D, H\u00e4nselmann A, Bauersachs J. The treatment of heart failure with reduced ejection fraction. Dtsch Arztebl Int. 2020, 117:376-86. 10.3238\/arztebl.2020.0376","journal-title":"Dtsch Arztebl Int"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X15666190709185011","article-title":"Contemporary pharmacologic management of heart failure with reduced ejection fraction: a review","volume":"16","author":"Egbuche O","year":"2020","unstructured":"Egbuche O, Hanna B, Onuorah I, Uko E, Taha Y, Ghali JK, Onwuanyi A. Contemporary pharmacologic management of heart failure with reduced ejection fraction: a review. Curr Cardiol Rev. 2020, 16:55-64. 10.2174\/1573403X15666190709185011","journal-title":"Curr Cardiol Rev"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008170.pub3","article-title":"First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension","volume":"11","author":"Chen YJ","year":"2018","unstructured":"Chen YJ, Li LJ, Tang WL, et al.. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. 2018, 11:CD008170. 10.1002\/14651858.CD008170.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2017.04.014","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America","volume":"23","author":"Yancy CW","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al.. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. J Card Fail. 2017, 23:628-51. 10.1016\/j.cardfail.2017.04.014","journal-title":"J Card Fail"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2006.08.001","article-title":"Angiotensin-converting enzyme inhibitor-associated angioedema","volume":"26","author":"Byrd JB","year":"2006","unstructured":"Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am. 2006, 26:725-37. 10.1016\/j.iac.2006.08.001","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn JN","year":"2001","unstructured":"Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001, 345:1667-75. 10.1056\/NEJMoa010713","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf S","year":"2008","unstructured":"Yusuf S, Teo KK, Pogue J, et al.. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008, 358:1547-59. 10.1056\/NEJMoa0801317","journal-title":"N Engl J Med"},{"key":"ref51","article-title":"Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium","volume":"82","author":"Bristow MR","year":"1990","unstructured":"Bristow MR, Hershberger RE, Port JD, et al.. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. 1990, 82:I12-25.","journal-title":"Circulation"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000035653.72855.bf","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer M","year":"2002","unstructured":"Packer M, Fowler MB, Roecker EB, et al.. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002, 106:2194-9. 10.1161\/01.cir.0000035653.72855.bf","journal-title":"Circulation"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.478","article-title":"ACC\/AHA versus ESC guidelines on heart failure: JACC guideline comparison","volume":"73","author":"van der Meer P","year":"2019","unstructured":"van der Meer P, Gaggin HK, Dec GW. ACC\/AHA versus ESC guidelines on heart failure: JACC guideline comparison. J Am Coll Cardiol. 2019, 73:2756-68. 10.1016\/j.jacc.2019.03.478","journal-title":"J Am Coll Cardiol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12527","article-title":"Safety of sacubitril\/valsartan initiated during hospitalization: data from a non-selected cohort","volume":"6","author":"L\u00f3pez-Azor JC","year":"2019","unstructured":"L\u00f3pez-Azor JC, Vicent L, Valero-Masa MJ, et al.. Safety of sacubitril\/valsartan initiated during hospitalization: data from a non-selected cohort. ESC Heart Fail. 2019, 6:1161-6. 10.1002\/ehf2.12527","journal-title":"ESC Heart Fail"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703100","article-title":"Diuretic treatment in heart failure","volume":"377","author":"Ellison DH","year":"2017","unstructured":"Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017, 377:1964-75. 10.1056\/NEJMra1703100","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"crossref","DOI":"10.1002\/j.1875-9114.1994.tb02848.x","article-title":"Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group","volume":"14","author":"Patterson JH","year":"1994","unstructured":"Patterson JH, Adams KF Jr, Applefeld MM, Corder CN, Masse BR. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy. 1994, 14:514-21.","journal-title":"Pharmacotherapy"},{"key":"ref58","article-title":"Six-week study of torsemide in patients with congestive heart failure","volume":"15","author":"Goebel KM","year":"1993","unstructured":"Goebel KM. Six-week study of torsemide in patients with congestive heart failure. Clin Ther. 1993, 15:1051-9.","journal-title":"Clin Ther"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (esc)developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al.. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (esc)developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016, 37:2129-200. 10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/0033-0620(84)90012-4","article-title":"Digitalis glycosides: mechanisms and manifestations of toxicity. Part I","volume":"26","author":"Smith TW","year":"1984","unstructured":"Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD. Digitalis glycosides: mechanisms and manifestations of toxicity. Part I. Prog Cardiovasc Dis. 1984, 26:413-58. 10.1016\/0033-0620(84)90012-4","journal-title":"Prog Cardiovasc Dis"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/0033-0620(84)90014-8","article-title":"Digitalis glycosides: mechanisms and manifestations of toxicity. Part II","volume":"26","author":"Smith TW","year":"1984","unstructured":"Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD. Digitalis glycosides: mechanisms and manifestations of toxicity. Part II. Prog Cardiovasc Dis. 1984, 26:495-540. 10.1016\/0033-0620(84)90014-8","journal-title":"Prog Cardiovasc Dis"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.05.064","article-title":"Digoxin discontinuation and outcomes in patients with heart failure with reduced ejection fraction","volume":"74","author":"Malik A","year":"2019","unstructured":"Malik A, Masson R, Singh S, et al.. Digoxin discontinuation and outcomes in patients with heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019, 74:617-27. 10.1016\/j.jacc.2019.05.064","journal-title":"J Am Coll Cardiol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.12.060","article-title":"Digoxin and mortality in patients with atrial fibrillation","volume":"71","author":"Lopes RD","year":"2018","unstructured":"Lopes RD, Rordorf R, De Ferrari GM, et al.. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018, 71:1063-74. 10.1016\/j.jacc.2017.12.060","journal-title":"J Am Coll Cardiol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1937121","article-title":"Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options","volume":"22","author":"Hulot JS","year":"2021","unstructured":"Hulot JS, Trochu JN, Donal E, Galinier M, Logeart D, De Groote P, Juilli\u00e8re Y. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. Expert Opin Pharmacother. 2021, 22:1847-55. 10.1080\/14656566.2021.1937121","journal-title":"Expert Opin Pharmacother"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.135","article-title":"Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)","volume":"16","author":"Pieske B","year":"2014","unstructured":"Pieske B, Butler J, Filippatos G, et al.. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014, 16:1026-38. 10.1002\/ejhf.135","journal-title":"Eur J Heart Fail"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong PW","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al.. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020, 382:1883-93. 10.1056\/NEJMoa1915928","journal-title":"N Engl J Med"},{"key":"ref67","article-title":"","author":"Vyas A","year":"2023","unstructured":"Vyas A, Onteddu N. Vericiguat. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574528\/."},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2006855","article-title":"Vericiguat\u2014another victory for targeting cyclic GMP in heart failure","volume":"382","author":"Burnett JC Jr","year":"2020","unstructured":"Burnett JC Jr. Vericiguat\u2014another victory for targeting cyclic GMP in heart failure. N Engl J Med. 2020, 382:1952-3. 10.1056\/NEJMe2006855","journal-title":"N Engl J Med"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-03023-7","article-title":"Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects","volume":"77","author":"Boettcher M","year":"2021","unstructured":"Boettcher M, Thomas D, Mueck W, Loewen S, Arens E, Yoshikawa K, Becker C. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. Eur J Clin Pharmacol. 2021, 77:527-37. 10.1007\/s00228-020-03023-7","journal-title":"Eur J Clin Pharmacol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01024-y","article-title":"Population pharmacokinetics and pharmacodynamics of vericiguat in patients with heart failure and reduced ejection fraction","volume":"60","author":"Ruehs H","year":"2021","unstructured":"Ruehs H, Klein D, Frei M, et al.. Population pharmacokinetics and pharmacodynamics of vericiguat in patients with heart failure and reduced ejection fraction. Clin Pharmacokinet. 2021, 60:1407-21. 10.1007\/s40262-021-01024-y","journal-title":"Clin Pharmacokinet"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00895-x","article-title":"Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat, a soluble guanylate cyclase stimulator: results from preclinical and phase I healthy volunteer studies","volume":"59","author":"Boettcher M","year":"2020","unstructured":"Boettcher M, Gerisch M, Lobmeyer M, et al.. Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat, a soluble guanylate cyclase stimulator: results from preclinical and phase I healthy volunteer studies. Clin Pharmacokinet. 2020, 59:1407-18. 10.1007\/s40262-020-00895-x","journal-title":"Clin Pharmacokinet"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2712","article-title":"Population pharmacokinetics of vericiguat in patients with heart failure with reduced ejection fraction: an integrated analysis","volume":"112","author":"Trujillo ME","year":"2022","unstructured":"Trujillo ME, Arrington L, Patel Y, et al.. Population pharmacokinetics of vericiguat in patients with heart failure with reduced ejection fraction: an integrated analysis. Clin Pharmacol Ther. 2022, 112:1061-9. 10.1002\/cpt.2712","journal-title":"Clin Pharmacol Ther"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13624","article-title":"Recent advances in pharmacological treatment of heart failure","volume":"51","author":"Iacoviello M","year":"2021","unstructured":"Iacoviello M, Palazzuoli A, Gronda E. Recent advances in pharmacological treatment of heart failure. Eur J Clin Invest. 2021, 51:e13624. 10.1111\/eci.13624","journal-title":"Eur J Clin Invest"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong PW","year":"2020","unstructured":"Armstrong PW, Lam CS, Anstrom KJ, et al.. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. JAMA. 2020, 324:1512-21. 10.1001\/jama.2020.15922","journal-title":"JAMA"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-020-07099-2","article-title":"Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis","volume":"35","author":"Aimo A","year":"2021","unstructured":"Aimo A, Pateras K, Stamatelopoulos K, et al.. Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis. Cardiovasc Drugs Ther. 2021, 35:1067-76. 10.1007\/s10557-020-07099-2","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial","volume":"314","author":"Gheorghiade M","year":"2015","unstructured":"Gheorghiade M, Greene SJ, Butler J, et al.. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 2015, 314:2251-62. 10.1001\/jama.2015.15734","journal-title":"JAMA"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study","volume":"38","author":"Pieske B","year":"2017","unstructured":"Pieske B, Maggioni AP, Lam CS, et al.. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017, 38:1119-27. 10.1093\/eurheartj\/ehw593","journal-title":"Eur Heart J"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2221","article-title":"Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial","volume":"23","author":"Voors AA","year":"2021","unstructured":"Voors AA, Mulder H, Reyes E, et al.. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. Eur J Heart Fail. 2021, 23:1313-21. 10.1002\/ejhf.2221","journal-title":"Eur J Heart Fail"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.08.008","article-title":"N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study","volume":"8","author":"Ezekowitz JA","year":"2020","unstructured":"Ezekowitz JA, O'Connor CM, Troughton RW, et al.. N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. JACC Heart Fail. 2020, 8:931-9. 10.1016\/j.jchf.2020.08.008","journal-title":"JACC Heart Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/202357-the-evolving-role-of-vericiguat-in-patients-with-chronic-heart-failure","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:07:33Z","timestamp":1707509253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/202357-the-evolving-role-of-vericiguat-in-patients-with-chronic-heart-failure"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":79,"URL":"https:\/\/doi.org\/10.7759\/cureus.49782","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}